Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.
Recruiting
N/A
Interventional Study
Obesity
Insulin Resistance
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 110 (estimated)
- Sponsor
- University Hospital, Rouen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to reduce the quality of life. In the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and IBS. Interestingly, experimental and clinical…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged from 18 to 65 years
* Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2)
* Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et \< 1.26 g/l)
* Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)
Exclusion Cri…
Contacts